Work

Immune subgroups and the tumor microenvironment as a potential new biomarker to assess response to immunotherapy

Year: 2019

Type: editorial

Abstract: Immunotherapy has emerged as a new standard of care therapeutic option for patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma. Following the recent presentation of Keynote-048, the use of Pembrolizumab either as a single agent or in combination with chemotherapy can be considered as first-line treatment for patients with measurable PD-L1 in their tumor or microenvironment (1).

Source: Chinese Clinical Oncology

DOI: 10.21037/cco.2019.08.15

Authors: Shawn Kothari, Everett E. Vokes

Institutions: University of Pennsylvania, University of Chicago, University of Chicago Medical Center, University of Chicago Medicine Comprehensive Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W2971369959

Cites: 4

Cited by:

Related to: 10